Cohen Investment Advisors LLC Has $2.82 Million Stake in Johnson & Johnson (NYSE:JNJ)

Cohen Investment Advisors LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,530 shares of the company’s stock after acquiring an additional 490 shares during the period. Johnson & Johnson comprises about 1.7% of Cohen Investment Advisors LLC’s portfolio, making the stock its 25th largest holding. Cohen Investment Advisors LLC’s holdings in Johnson & Johnson were worth $2,824,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. WCG Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 13.0% during the 2nd quarter. WCG Wealth Advisors LLC now owns 12,124 shares of the company’s stock worth $1,772,000 after acquiring an additional 1,395 shares during the period. Richardson Financial Services Inc. lifted its holdings in Johnson & Johnson by 21.5% during the 2nd quarter. Richardson Financial Services Inc. now owns 497 shares of the company’s stock valued at $73,000 after purchasing an additional 88 shares during the last quarter. Brighton Jones LLC boosted its position in Johnson & Johnson by 35.9% during the second quarter. Brighton Jones LLC now owns 49,470 shares of the company’s stock worth $7,231,000 after purchasing an additional 13,078 shares during the period. Trust Investment Advisors bought a new position in shares of Johnson & Johnson in the second quarter valued at about $291,000. Finally, Retirement Investment Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $208,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on JNJ shares. Bank of America lowered their price target on shares of Johnson & Johnson from $166.00 to $160.00 and set a “neutral” rating on the stock in a report on Friday. Citigroup dropped their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Morgan Stanley lifted their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $174.29.

Insider Buying and Selling at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, with a total value of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $147.03 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $353.99 billion, a PE ratio of 21.28, a PEG ratio of 2.30 and a beta of 0.51. The firm has a 50 day moving average of $148.68 and a 200-day moving average of $155.96. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same period in the prior year, the company earned $2.66 earnings per share. The company’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities research analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.37%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.